查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1974011

肌萎縮側索硬化症 (ALS) 市場分析及預測（至 2035 年）：按類型、產品、服務、技術、組件、應用、設備、流程和最終用戶分類

Amyotrophic Lateral Sclerosis Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, Device, Process, End User
出版日期: | 出版商: Global Insight Services | 英文 304 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

肌萎縮側索硬化症 (ALS) 市場預計將從 2024 年的 12 億美元成長到 2034 年的 21 億美元，複合年成長率約為 5.8%。 ALS 市場涵蓋用於治療 ALS（進行性神經退化性疾病）的藥物、診斷和支持療法。基因療法的進步、新藥研發以及研究經費的增加是推動該市場成長的主要因素。人們對 ALS 的認知不斷提高以及診斷技術的進步正在推動對創新治療方法的需求。策略聯盟和監管支援進一步加速了市場成長，其重點在於延長患者壽命和提高患者生活品質。

肌萎縮側索硬化症 (ALS) 市場正經歷著蓬勃發展，這主要得益於治療方案的進步和診斷技術的創新。其中，治療領域成長最為迅猛，主要由疾病修正治療療法和對症療法推動。創新藥物配方和新型治療方法方案的出現，進一步促進了該領域的擴張。診斷領域成長排名第二，主要得益於生物標記技術和基因檢測技術的顯著進步。這些創新正在加強早期診斷和個人化治療方案的實施。研發活動也不斷加強，並著重於神經保護劑和再生醫學。新興生物技術和基因療法備受矚目，並有望徹底改變 ALS 的治療模式。人工智慧在藥物研發和病患管理的應用，進一步提升了市場成長前景。製藥公司與研究機構之間的合作正在促進創新，並加速有效解決方案的發展。公眾對 ALS 的認知和教育程度的提高，也推動了對先進醫療保健解決方案的需求成長。

市場區隔
類型 散發性肌萎縮側索硬化症，遺傳性性肌萎縮側索硬化症
產品 Riluzole、Edaravone、Tiracemtive、Nudextre、馬賽替尼
服務 病患支援服務、諮詢服務、臨床試驗服務
科技 生物技術、藥物基因體學、基因治療、幹細胞治療
成分 活性成分、添加劑
目的 醫院、門診手術中心、研究機構
裝置 非侵入性通氣，經皮視鏡胃造瘻術
流程 藥物研發、臨床試驗、監理核准、商業化
最終用戶 醫療保健提供者、患者、製藥公司

市場概況：

肌萎縮側索硬化症 (ALS) 市場正經歷動態變化，主要企業佔顯著的市場佔有率。定價策略不斷演變以應對競爭壓力和患者需求，從而催生出創新的定價模式。生物技術的進步和對疾病機制更深入的理解正推動新產品的上市，進而促進市場發展。這些進展在拓展治療選擇、改善病患預後的同時，也加劇了市場競爭。競爭基準研究揭示了主要企業之間的激烈競爭，而策略聯盟和合作研究正在塑造市場動態。監管的影響至關重要，北美和歐洲的監管機構制定了嚴格的指導方針，對市場准入和擴大策略產生影響。 ALS 市場的特點是研發投入巨大，主要集中在新型治療方法和個人化醫療方面。專利到期和非專利處方藥的上市進一步加劇了市場的複雜性，預計將改變競爭格局，並推動市場發展。

主要趨勢和促進因素：

在研發進步的推動下，肌萎縮側索硬化症 (ALS) 市場持續發展。神經系統研究經費的增加正在加速創新治療方法的發現。新藥認證和臨床試驗的擴展正在拓寬治療選擇，並滿足 ALS 治療領域尚未滿足的需求。個人化醫療的興起是一大趨勢，基因檢測使得針對個別患者特徵的標靶治療成為可能。這種方法提高了治療效果和患者預後。製藥公司與研究機構之間的合作正在加速創新步伐。包括遠端醫療和遠距監測在內的數位健康技術正在改變患者管理方式，並改善醫療服務的可近性。這些技術能夠實現即時數據收集，從而加強疾病追蹤和介入策略。對孤兒藥研發的監管支持和獎勵正在創造一個有利於市場成長的環境。隨著相關人員利用這些趨勢推動診斷、治療和患者照護方面的進步，ALS 市場有望進一步擴張。

壓制與挑戰：

肌萎縮側索硬化症 (ALS) 市場面臨許多重大限制和挑戰。其中一個主要限制因素是藥物研發和臨床試驗的高成本。這種經濟負擔限制了新進入者，並減緩了創新步伐。此外，ALS 的罕見性限制了符合臨床研究條件的患者數量，導致受試者招募困難，並延長了研究週期。另一個挑戰是缺乏確診檢測方法。這會延誤診斷和治療啟動，影響患者的預後。 ALS 病理的複雜性也阻礙了有效治療方法的發展。研究人員在理解疾病的潛在機制方面面臨許多困難。此外，監管障礙和新治療方法嚴格的核准流程也會延緩其上市。同時，亟需加強醫療專業人員和民眾的認知和教育。這種知識差距可能會阻礙早期診斷和干涉，進而影響整體市場成長。

目錄

第1章摘要整理

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 散發性肌萎縮性側索硬化症
    • 遺傳性肌萎縮性側索硬化症
  • 市場規模及預測：依產品分類
    • Riluzole
    • Edaravone
    • 提拉塞姆奇布
    • 紐德克斯特
    • 馬西替尼
  • 市場規模及預測：依服務分類
    • 病人支援服務
    • 諮詢服務
    • 臨床試驗服務
  • 市場規模及預測：依技術分類
    • 生物技術
    • 藥理基因體學
    • 基因治療
    • 幹細胞療法
  • 市場規模及預測：依組件分類
    • 活性成分
    • 添加劑
  • 市場規模及預測：依應用領域分類
    • 醫院
    • 門診手術中心
    • 研究機構
  • 市場規模及預測：依設備分類
    • 非侵入性通氣
    • 經皮視鏡胃造瘻術
  • 市場規模及預測：依製程分類
    • 藥物研發
    • 臨床試驗
    • 獲得監管機構的核准
    • 商業化
  • 市場規模及預測：依最終用戶分類
    • 醫療保健提供者
    • 病人
    • 製藥公司

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • BrainStorm Cell Therapeutics
  • Mitsubishi Tanabe Pharma Corporation
  • Orphazyme
  • AB Science
  • MediciNova
  • Biogen
  • Ionis Pharmaceuticals
  • Cytokinetics
  • Amylyx Pharmaceuticals
  • Apellis Pharmaceuticals
  • Anelixis Therapeutics
  • Treeway
  • Genervon Biopharmaceuticals
  • NeuroSense Therapeutics
  • QurAlis

第9章 關於我們

簡介目錄
Product Code: GIS33612

Amyotrophic Lateral Sclerosis Market is anticipated to expand from $1.2 billion in 2024 to $2.1 billion by 2034, growing at a CAGR of approximately 5.8%. The Amyotrophic Lateral Sclerosis (ALS) Market encompasses pharmaceuticals, diagnostics, and supportive care aimed at managing ALS, a progressive neurodegenerative disorder. The market is driven by advancements in gene therapy, novel drug development, and increased research funding. Rising awareness and improved diagnostic techniques are propelling demand for innovative treatments. Strategic collaborations and regulatory support further enhance market growth, focusing on extending patient lifespans and improving quality of life.

The Amyotrophic Lateral Sclerosis (ALS) Market is experiencing dynamic growth, propelled by advancements in therapeutic options and diagnostic innovations. The therapeutics segment is the top performer, with disease-modifying therapies and symptomatic treatments leading the charge. Innovative drug formulations and novel therapeutic classes are driving this segment's expansion. The diagnostics segment follows as the second highest performer, with significant advancements in biomarker technologies and genetic testing. These innovations are enhancing early diagnosis and personalized treatment approaches. Research and development activities are intensifying, focusing on neuroprotective agents and regenerative medicine. Emerging biotechnologies and gene therapies are capturing attention, promising to revolutionize ALS treatment paradigms. The integration of artificial intelligence in drug discovery and patient management is further augmenting growth prospects. Collaborations between pharmaceutical companies and research institutions are fostering innovation, accelerating the development of effective solutions. The increasing awareness and advocacy for ALS are also contributing to heightened demand for advanced healthcare solutions.

Market Segmentation
TypeSporadic ALS, Familial ALS
ProductRiluzole, Edaravone, Tirasemtiv, Nuedexta, Masitinib
ServicesPatient Support Services, Consultation Services, Clinical Trial Services
TechnologyBiotechnology, Pharmacogenomics, Gene Therapy, Stem Cell Therapy
ComponentActive Pharmaceutical Ingredients, Excipients
ApplicationHospitals, Ambulatory Surgical Centers, Research Institutes
DeviceNon-Invasive Ventilation, Percutaneous Endoscopic Gastrostomy
ProcessDrug Development, Clinical Trials, Regulatory Approval, Commercialization
End UserHealthcare Providers, Patients, Pharmaceutical Companies

Market Snapshot:

The Amyotrophic Lateral Sclerosis (ALS) market is witnessing dynamic shifts with significant market share held by leading pharmaceutical companies. Pricing strategies are evolving in response to competitive pressures and patient needs, with innovative pricing models emerging. New product launches are invigorating the market, driven by advancements in biotechnology and a deeper understanding of disease mechanisms. These developments are enhancing treatment options and improving patient outcomes, fostering a competitive landscape. Competition benchmarking reveals a robust rivalry among key players, with strategic partnerships and collaborations shaping the market dynamics. Regulatory influences are pivotal, as agencies in North America and Europe impose stringent guidelines, impacting market entry and expansion strategies. The ALS market is characterized by high R&D investments, focusing on novel therapeutics and personalized medicine. The landscape is further complicated by patent expirations and generic drug entries, which are expected to alter the competitive equilibrium and drive market evolution.

Geographical Overview:

The Amyotrophic Lateral Sclerosis (ALS) market is witnessing varied growth patterns across different regions. North America remains at the forefront, driven by advanced healthcare infrastructure and significant research investments. The presence of leading pharmaceutical companies and robust funding for ALS research further bolster market expansion. Europe follows, with increased awareness and government initiatives supporting ALS treatment advancements. Asia Pacific is emerging as a promising growth pocket, propelled by rising healthcare expenditure and expanding patient awareness. Countries like China and Japan are at the helm, investing heavily in research and development. Meanwhile, Latin America and the Middle East & Africa are gradually gaining momentum. These regions are recognizing the need for improved healthcare frameworks and are beginning to channel resources towards ALS treatment and research. Brazil and South Africa are notable emerging players, showing potential for substantial market growth in the coming years.

Key Trends and Drivers:

The Amyotrophic Lateral Sclerosis (ALS) market is evolving, driven by advancements in research and therapeutic development. Increased funding for neurological research is propelling the discovery of innovative treatment modalities. New drug approvals and clinical trials are expanding therapeutic options, addressing unmet medical needs in ALS care. The rise of personalized medicine is a key trend, with genetic testing enabling targeted therapies tailored to individual patient profiles. This approach enhances treatment efficacy and patient outcomes. Collaborations between pharmaceutical companies and research institutions are accelerating the pace of innovation. Digital health technologies, including telemedicine and remote monitoring, are transforming patient management, improving accessibility to care. These technologies facilitate real-time data collection, enhancing disease tracking and intervention strategies. Regulatory support and incentives for orphan drug development are fostering a conducive environment for market growth. The ALS market is poised for expansion as stakeholders capitalize on these trends, driving progress in diagnosis, treatment, and patient care.

Restraints and Challenges:

The Amyotrophic Lateral Sclerosis (ALS) market encounters several substantial restraints and challenges. A significant restraint is the high cost of drug development and clinical trials. This financial burden limits the entry of new players and slows the pace of innovation. Additionally, the rarity of ALS results in a limited patient pool for clinical studies, which complicates the recruitment process and extends timelines. Another challenge is the lack of definitive diagnostic tests. This results in delayed diagnosis and treatment initiation, affecting patient outcomes. The complexity of ALS pathology also hinders the development of effective therapies. Researchers face difficulties in understanding the disease's underlying mechanisms. Furthermore, regulatory hurdles and stringent approval processes for new treatments can delay market entry. There is also a significant need for increased awareness and education among healthcare professionals and the public. This gap in knowledge can impede early diagnosis and intervention, affecting overall market growth.

Key Players:

BrainStorm Cell Therapeutics, Mitsubishi Tanabe Pharma Corporation, Orphazyme, AB Science, MediciNova, Biogen, Ionis Pharmaceuticals, Cytokinetics, Amylyx Pharmaceuticals, Apellis Pharmaceuticals, Anelixis Therapeutics, Treeway, Genervon Biopharmaceuticals, NeuroSense Therapeutics, QurAlis

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by Device
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by End User

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Sporadic ALS
    • 4.1.2 Familial ALS
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Riluzole
    • 4.2.2 Edaravone
    • 4.2.3 Tirasemtiv
    • 4.2.4 Nuedexta
    • 4.2.5 Masitinib
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Patient Support Services
    • 4.3.2 Consultation Services
    • 4.3.3 Clinical Trial Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Biotechnology
    • 4.4.2 Pharmacogenomics
    • 4.4.3 Gene Therapy
    • 4.4.4 Stem Cell Therapy
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 Active Pharmaceutical Ingredients
    • 4.5.2 Excipients
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Ambulatory Surgical Centers
    • 4.6.3 Research Institutes
  • 4.7 Market Size & Forecast by Device (2020-2035)
    • 4.7.1 Non-Invasive Ventilation
    • 4.7.2 Percutaneous Endoscopic Gastrostomy
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Drug Development
    • 4.8.2 Clinical Trials
    • 4.8.3 Regulatory Approval
    • 4.8.4 Commercialization
  • 4.9 Market Size & Forecast by End User (2020-2035)
    • 4.9.1 Healthcare Providers
    • 4.9.2 Patients
    • 4.9.3 Pharmaceutical Companies

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 Device
      • 5.2.1.8 Process
      • 5.2.1.9 End User
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 Device
      • 5.2.2.8 Process
      • 5.2.2.9 End User
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 Device
      • 5.2.3.8 Process
      • 5.2.3.9 End User
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 Device
      • 5.3.1.8 Process
      • 5.3.1.9 End User
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 Device
      • 5.3.2.8 Process
      • 5.3.2.9 End User
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 Device
      • 5.3.3.8 Process
      • 5.3.3.9 End User
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 Device
      • 5.4.1.8 Process
      • 5.4.1.9 End User
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 Device
      • 5.4.2.8 Process
      • 5.4.2.9 End User
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 Device
      • 5.4.3.8 Process
      • 5.4.3.9 End User
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 Device
      • 5.4.4.8 Process
      • 5.4.4.9 End User
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 Device
      • 5.4.5.8 Process
      • 5.4.5.9 End User
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 Device
      • 5.4.6.8 Process
      • 5.4.6.9 End User
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 Device
      • 5.4.7.8 Process
      • 5.4.7.9 End User
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 Device
      • 5.5.1.8 Process
      • 5.5.1.9 End User
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 Device
      • 5.5.2.8 Process
      • 5.5.2.9 End User
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 Device
      • 5.5.3.8 Process
      • 5.5.3.9 End User
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 Device
      • 5.5.4.8 Process
      • 5.5.4.9 End User
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 Device
      • 5.5.5.8 Process
      • 5.5.5.9 End User
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 Device
      • 5.5.6.8 Process
      • 5.5.6.9 End User
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 Device
      • 5.6.1.8 Process
      • 5.6.1.9 End User
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 Device
      • 5.6.2.8 Process
      • 5.6.2.9 End User
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 Device
      • 5.6.3.8 Process
      • 5.6.3.9 End User
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 Device
      • 5.6.4.8 Process
      • 5.6.4.9 End User
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 Device
      • 5.6.5.8 Process
      • 5.6.5.9 End User

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 BrainStorm Cell Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Mitsubishi Tanabe Pharma Corporation
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Orphazyme
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 AB Science
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 MediciNova
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Biogen
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Ionis Pharmaceuticals
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Cytokinetics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Amylyx Pharmaceuticals
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Apellis Pharmaceuticals
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Anelixis Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Treeway
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Genervon Biopharmaceuticals
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 NeuroSense Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 QurAlis
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us